Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with 64CuCl2 in human breast cancer xenograft model

Journal of Nuclear Medicine

Volumn 55, Issue 10, 2014, Pages 1692-1698

  Kim, Kwang Il ^a   Jang, Su Jin ^a   Park, Ju Hui ^a   Lee, Yong Jin ^a   Lee, Tae Sup ^a   Woo, Kwang Sun ^a   Park, Hyun ^a   Choe, Jae Gol ^b   An, Gwang Il ^a   Kang, Joo Hyun ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b College of Medicine   (South Korea)

Author keywords

64Cu; Cisplatin; HCTR1; PET; Reporter gene

Indexed keywords

CISPLATIN; COPPER 64; COPPER CHLORIDE 64; LENTIVIRUS VECTOR; RNA; UNCLASSIFIED DRUG; CATION TRANSPORT PROTEIN; COPPER; CUPRIC CHLORIDE; SLC31A1 PROTEIN, HUMAN; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER MODEL; CELL CLONE; CELL SURVIVAL; CELL VIABILITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG TUMOR LEVEL; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN COPPER TRANSPORTER 1 GENE; LENTIVIRUS INFECTION; MDA MB 231 CELL LINE; MOUSE; NONHUMAN; PET-CT SCANNER; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; BREAST TUMOR; DRUG SCREENING; GENE EXPRESSION REGULATION; KINETICS; METABOLISM; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CISPLATIN; COPPER; COPPER RADIOISOTOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; KINETICS; MICE; POSITRON-EMISSION TOMOGRAPHY; TETRAZOLIUM SALTS; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907485249     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.141127     Document Type: Article

References (30)

1. Wessling-Resnick M. Understanding copper uptake at the molecular level. Nutr Rev. 2002;60:177-179.
2. Kaler SG, Holmes CS, Goldstein DS, et al. Neonatal diagnosis and treatment of Menkes disease. N Engl J Med. 2008;358:605-614.
3. Das SK, Ray K.Wilson's disease: an update. Nat Clin Pract Neurol. 2006;2:482-493.
4. Dancis A, Yuan DS, Haile D, et al. Molecular characterization of a copper transport protein in S. cerevisiae: an unexpected role for copper in iron transport. Cell. 1994;76:393-402.
5. Zhou B, Gitschier J. hCTR1: a human gene for copper uptake identified by complementation in yeast. Proc Natl Acad Sci USA. 1997;94:7481-7486.
6. Lee J, Prohaska JR, Dagenais SL, Glover TW, Thiele DJ. Isolation of a murine copper transporter gene, tissue specific expression and functional complementation of a yeast copper transport mutant. Gene. 2000;254:87-96.
7. Lee J, Pena MM, Nose Y, Thiele DJ. Biochemical characterization of the human copper transporter Ctr1. J Biol Chem. 2002;277:4380-4387.
8. Kang JH, Chung JK. Molecular-genetic imaging based on reporter gene expression. J Nucl Med. 2008;49(suppl 2):164S-179S.
9. Shokeen M, Wadas TJ. The development of copper radiopharmaceuticals for imaging and therapy. Med Chem. 2011;7:413-429.
10. Kang JH, Chung JK, Lee YJ, et al. Establishment of a human hepatocellular carcinoma cell line highly expressing sodium iodide symporter for radionuclide gene therapy. J Nucl Med. 2004;45:1571-1576.
11. Knoop K, Schwenk N, Dolp P, et al. Stromal targeting of sodium iodide symporter using mesenchymal stem cells allows enhanced imaging and therapy of hepatocellular carcinoma. Hum Gene Ther. 2013;24: 306-316.
12. Haddad D, Zanzonico PB, Carlin S, et al. A vaccinia virus encoding the human sodium iodide symporter facilitates long-term image monitoring of virotherapy and targeted radiotherapy of pancreatic cancer. J Nucl Med. 2012;53:1933-1942.
13. Larson CA, Blair BG, Safaei R, Howell SB. The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol Pharmacol. 2009;75:324-330.
14. Holzer AK, Samimi G, Katano K, et al. The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 2004;66:817-823.
15. Kim JY, Park H, Lee JC, et al. A simple Cu-64 production and its application of Cu-64 ATSM. Appl Radiat Isot. 2009;67:1190-1194.
16. Kim KI, Kang JH, Chung JK, et al. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. J Nucl Med. 2007;48:1553-1561.
17. Kuo YM, Zhou B, Cosco D, Gitschier J. The copper transporter CTR1 provides an essential function in mammalian embryonic development. Proc Natl Acad Sci USA. 2001;98:6836-6841.
18. Holzer AK, Varki NM, Le QT, Gibson MA, Naredi P, Howell SB. Expression of the human copper influx transporter 1 in normal and malignant human tissues. J Histochem Cytochem. 2006;54:1041-1049.
19. Lee YY, Choi CH, Do IG, et al. Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy. Gynecol Oncol. 2011;122:361-365.
20. Peng F, Lu X, Janisse J, Muzik O, Shields AF. PET of human prostate cancer xenografts in mice with increased uptake of 64CuCl2. J Nucl Med. 2006;47:1649-1652.
21. Zhang H, Cai H, Lu X, Muzik O, Peng F. Positron emission tomography of human hepatocellular carcinoma xenografts in mice using copper (II)-64 chloride as a tracer with copper (II)-64 chloride. Acad Radiol. 2011;18:1561-1568.
22. Qin C, Liu H, Chen K, et al. Theranostics of malignant melanoma with 64CuCl2. J Nucl Med. 2014;55:812-817.
23. Cai H, Wu JS, Muzik O, Hsieh JT, Lee RJ, Peng F. Reduced 64Cu uptake and tumor growth inhibition by knockdown of human copper transporter 1 in xenograft mouse model of prostate cancer. J Nucl Med. 2014;55:622-628.
24. Brady DC, Crowe MS, Turski ML, et al. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature. 2014;509:492-496.
25. Gupta A, Lutsenko S. Human copper transporters: mechanism, role in human diseases and therapeutic potential. Future Med Chem. 2009;1:1125-1142.
26. Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol. 2010; 77:887-894.
27. More SS, Akil O, Ianculescu AG, Geier EG, Lustig LR, Giacomini KM. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci. 2010; 30:9500-9509.
28. Beretta GL, Gatti L, Tinelli S, et al. Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and-resistant cells. Biochem Pharmacol. 2004;68:283-291.
29. Martens-de Kemp SR, Dalm SU, Wijnolts FM, et al. DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells. PLoS ONE. 2013;8:e61555.
30. Ivy KD, Kaplan JH. A re-evaluation of the role of hCTR1, the human highaffinity copper transporter, in platinum-drug entry into human cells. Mol Pharmacol. 2013;83:1237-1246.